135O_PR: plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
If T790M is detected in peripheral blood, treatment with third-generation EGFR TKIs is justified.
“In the event that a T790M mutation in peripheral blood is observed, treatment with third-generation EGFR TKIs is justified [130].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited by
Sorted by citations
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631 · see citing works
Precision Oncology: Who, How, What, When, and When Not?
Schwartzberg, L. S., Kim, E. S., Liu, D., & Schrag, D. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_174176 · Cited by 281 · see citing works
Sullivan, I., & Planchard, D. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2016.00076 · Cited by 113 · see citing works
“In cases when the T790M mutation is identified in peripheral blood, treatment with thirdgeneration EGFR TKIs is justified (25).”
BackgroundThe Importance of Biopsy in the Era of Molecular Medicine
Ziv, E., Durack, J. C., & Solomon, S. B. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000228 · Cited by 78 · see citing works
“In 1 study, there was high concordance between T790Mpositive plasma and T790M tissue biopsies, and in a second study, there was high correlation between T790M-positive plasma and response rates to T790M-targeting EGFR inhibitor.(63,64) However, unstable molecules such as RNA and protein are less likely to be reliably…”
BackgroundLiquid biopsy genotyping in lung cancer: ready for clinical utility?
Huang, W.-L., Chen, Y.-L., Yang, S., Ho, C., Wei, F., Wong, D. T., Su, W., & Lin, C. (2017) · Oncotarget · doi:10.18632/oncotarget.14613 · Cited by 57 · see citing works
“The finding was compatible with that of Oxnard et al [93, 109], wherein cases that were T790M negative in the tumor but were T790M positive in the plasma were further studied by use of orthogonal plasma genotyping assays such as ddPCR or Cobas®, and 78% of these cases could be confirmed as positive.”
ResultInfluentialLiu, Y., Sun, L., Xiong, Z., Sun, X., Zhang, S., Ma, J., & Han, C. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s133082 · Cited by 54 · see citing works
“A moderate concordant rate of 65% in E20 T790M mutations between tumor and plasma ctDNA has been reported; this contrasts the high concordant rate of 90% in E19del and E21 L858R mutations.(23,24) Recently, researchers have also explored the relationship between prognosis and pretreatment T790M mutation.”
ResultFirst-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?
Bulbul, A., & Husain, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00094 · Cited by 27 · see citing works
Noncoding RNAs and Liquid Biopsy in Lung Cancer: A Literature Review
Haranguș, A., Berindan‐Neagoe, I., Todea, D. A., Şimon, I., & Șimon, M. (2019) · Diagnostics · doi:10.3390/diagnostics9040216 · Cited by 12 · see citing works
“Oxnard et al. (2016) conducted a study on 216 patients and found that plasma genotyping for T790M using beads, emulsions, amplification, and magnetics (BEAM) had a 30% false-negative rate [140].”
MethodRemón, J., & Besse, B. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000081 · Cited by 9 · see citing works
Leprieur, E. G., Cortot, A. B., Cadranel, J. L., & Wislez, M. (2016) · Bulletin du Cancer · doi:10.1016/j.bulcan.2016.06.007 · Cited by 3 · see citing works
“Des données actualisées ont été présentées à l’ELCC cette année sur 216 patients de la phase I avec possibilité de comparaison biopsie et plasma [28].”
Personalizing Therapy for Acquired Resistance to EGFR Kinase Inhibitors in Advanced NSCLC
Sacher, A. G., & Oxnard, G. R. (2016) · American Journal of Hematology / Oncology® · Cited by 2 · see citing works
Self-citationPeters, S., & Zimmermann, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-70253-7_3 · Cited by 1 · see citing works
Aldaco-Sarvide, F., Valle-Solís, A. A. E., Acosta-Gutiérrez, D. N., Añorve-Bailón, D., Ballesteros-Pino, D. A., Cervantes-Sánchez, G., Cárdenas-Cárdenas, E., Cruz-López, J. C., Díaz-Alvarado, M. G., Durán-Gil, C., et al. (2020) · Latin American Journal of Clinical Sciences and Medical Technology · doi:10.34141/ljcs7299157
- Authors
- Oxnard, G. R., Thress, K. S., Alden, R. S., Lawrance, R., Paweletz, C. P., Cantarini, M., Barrett, C., Yang, J., & Jänne, P.
- Affiliations
- Dana-Farber Cancer Institute (US)
- AstraZeneca (United States) (US)
- AstraZeneca (United Kingdom) (GB)
- National Taiwan University Hospital (TW)
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 11
- Issue
- 4
- Pages
- S154
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2341795159
- Cited by
- 13
- References
- 0
- Citations by year
- 2020: 1 · 2019: 1 · 2018: 2 · 2017: 4 · 2016: 5
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- Funders
- Pfizer
- AstraZeneca
- Dana-Farber Cancer Institute
- Astellas Pharma
- Chugai Pharmaceutical
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- osimertinib, plasma genotyping, non-small cell lung cancer, T790M mutation, EGFR tyrosine kinase inhibitors, predictive biomarkers, liquid biopsy, metastatic lung cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
